From treating AIDS drugs to increasing the treatment of COVID-19 indications, how does Chang Junbiao do
Time of Update: 2022-09-21
One productTwo missionsAt the beginning of 2020, the new crown epidemic broke out in China, and the research on special drugs could not be delayed.
The Health and Health Commission has notified clinics and clinics that more than 500 kinds of drugs can be used
Time of Update: 2022-02-22
02 Variation 2: Rearrange and combine into twenty-two categories In addition to the increase in the total number, the drugs in the "Catalog" have been re-arranged and combined .
11 new diabetes drugs are added 03Change 3.
Oyster Point Pharma announced that it has reached an exclusive license agreement with Jixing Pharmaceutical to develop and commercialize two drugs for the treatment of dry eye in Greater China
Time of Update: 2021-08-14
Jixing Pharmaceutical will develop and commercialize OC-01 (varenicline) and OC-02 (simpinicline) nasal sprays for dry eye patients in Greater China Oyster Point Pharma will receive a down payment of US$17.
Circulation: The sooner the better
Time of Update: 2021-08-14
For patients with atrial fibrillation, the main goal of treatment is to control symptoms and prevent heart failure and prevention of arterial thrombosis embolism, especially stroke .
DRG is difficult to promote the development of the off-site market
Time of Update: 2020-12-30
the number of outpatient visits to level III hospitals rose from 1.5 billion in 2015 to 2 billion in 2019, and the growth rate from 8.67 percent in 2016 to 11.35 percent in 2019 was directly exceeded, mainly due to the rapid decline in drug prices after the national drug collection, and the return of patients to large hospitals.
Jia and biopharmacemics "Invlisi monoanti" biosynthic drugs declared on the market
Time of Update: 2020-11-08
The new drug application is based on a three-phase trial in China of multi-center, randomized, double-blind, parallel control to assess the safety and efficacy of GB242 contrast g (Invlisi monoantigen) and methotrexate combinations at a dose of 3 mg/kg intravenously treated patients with rheumatoid arthritis.
A number of varieties are expected to enter the 2020 version of national health insurance
Time of Update: 2020-08-24
Overall, according to the document, by December 31, 2019, the latest version of the provincial medical insurance drug catalog entered the five (inclusive) drugs, only to have the opportunity to return to enter the national health insurance drug catalog, the state access to past data, the current pharmaceutical companies do not have any provinces of the number of remedial measures.
J Hepatol: the researchers showed the potential of targeting cancer stem cells to treat liver cancer
Time of Update: 2019-10-17
October 17, 2019 / BIOON / -- liver cancer is the second largest cancer-related death cause in the world The most common primary liver cancer in adults is called liver cell carcinoma (HCC) About 78000
Cornerstone pharmaceutical signed strategic cooperation agreement with Suzhou University
Time of Update: 2018-01-20
Source: Yaodu 2018-01-20 cornerstone Pharmaceutical (Suzhou) Co., Ltd and Suzhou University jointly held the "cornerstone pharmaceutical - Suzhou University Scientific Research Cooperation Seminar" in